Poster Presentations:
Jankowski et al., “A Phase 2, Multi-Center, Open-Label, Dose-Optimization Study Evaluating Telomere Targeting Agent THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC – Preliminary Results”, European Society for Medical Oncology (ESMO) Congress 2023. (Click to view poster, PDF)
ESMO Congress 2023 Support Presentation. (Click to view presentation, PDF)
Gryaznov et al., Telomerase-Driven Telomeric DNA Modification in Cancer Cells Leads to Efficient Induction of cGAS-mediated Innate and Adaptive Immune Responses, Society for Immunotherapy of Cancer (SITC) 2021 Conference. (Click to view poster, PDF 820KB)
Publications:
Mender et al., Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Cancer Cell (2020), https:// doi.org/10.1016/j.ccell.2020.05.020 https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30270-1
Mender et al. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells. Oncoscience. 2015 Aug 22;2(8):693-5. https://www.ncbi.nlm.nih.gov/pubmed/26425659
Mender, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer Discovery. 2015 Jan;5(1):82-95. https://www.ncbi.nlm.nih.gov/pubmed/25516420
Mender et al. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 2018 Aug;20(8):826-837. https://www.ncbi.nlm.nih.gov/pubmed/30015158
Reyes-Uribe et al. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene. 2018 Jul;37(30):4058-4072. https://www.ncbi.nlm.nih.gov/pubmed/29695835
Sengupta et al. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul;17(7):1504-1514. https://www.ncbi.nlm.nih.gov/pubmed/29654065
Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019 May;20(5):299-309. https://www.ncbi.nlm.nih.gov/pubmed/30760854
Zhang et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. https://www.ncbi.nlm.nih.gov/pubmed/29563139
Zhang G, Shay JW. Inducing rapid telomere irreparable damage in telomerase-expressing cancers. Oncotarget. 2018 Nov 9;9(88):35803-35804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254679/